Effects of YM-14673, a thyrotropin-releasing hormone analogue, injected into the shell and the core of the nucleus accumbens on production of repetitive jaw movements in rats: comparison with the effects of a dopamine D1 and D2 receptor agonist combination.
The present study examined whether the shell and the core of the nucleus accumbens play a differential role in the display of YM-14673-induced jaw movements in rats. For that purpose the effects of YM-14673 were compared to those of a SKF 82958 and quinpirole combination, a dopamine D1 and a D2 receptor agonist respectively, that is known to functionally differentiate these two subregions of the nucleus. Consistent with the previous report, bilateral injections of a mixture of SKF 82958 (5 micrograms) and quinpirole (10 micrograms) into the shell of the nucleus accumbens produced repetitive jaw movements, whereas similar injections of the mixture into the core did not induce such an effect. In contrast, there was no regional difference in the effects of YM-14673 on the production of repetitive jaw movements. Thus, both bilateral injections of YM-14673 (0.1 or 1.0 microgram) into the shell or the core produced similar repetitive jaw movements in a dose-related manner. Moreover, the pattern of oral movements induced by YM-14673 differed from that induced by the mixture of SKF 82958 and quinpirole; frequent tongue protrusions were evident in rats treated with the mixture but were not seen in YM-14673-treated rats. It therefore appears that, unlike the effects of the mixture of dopamine D1 and D2 receptor agonists, the effects of YM-14673 in the shell on the production of rat jaw movements do not differ from the effects of the compound in the core.
Adachi
K
K
Department of Pharmacology, Nihon University School of Dentistry, Tokyo, Japan.
Hirose
N
N
Fujioka
H
H
Yoneshige
N
N
Koshikawa
N
N
D000818:Animals; D001384:Azetidines / Q000008:administration & dosage / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology*; D004151:Dipeptides / Q000008:administration & dosage / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004576:Electromyography / Q000187:drug effects; D007276:Injections, Intraventricular; D008297:Male; D008334:Mandible / Q000503:physiopathology*; D008406:Masseter Muscle / Q000503:physiopathology; D009055:Mouth / Q000503:physiopathology; D009068:Movement; D009334:Neck Muscles / Q000503:physiopathology; D009714:Nucleus Accumbens / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D019257:Quinpirole / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000819:agonists*; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014059:Tongue / Q000503:physiopathology
D001384:Azetidines; D001552:Benzazepines; D004151:Dipeptides; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D019257:Quinpirole; D013973:Thyrotropin-Releasing Hormone; C054995:azetirelin; C071262:SK&F 82958